ViiV Healthcare and the pan-Canadian Pharmaceutical Alliance successfully finalise negotiations for Apretude for HIV-1 pre-exposure prophylaxis

13 February 2025 - ViiV Healthcare is pleased to announce it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance ...

Read more →

Novartis receives Health Canada approval for Fabhalta oral treatment for adult patients with paroxysmal nocturnal haemoglobinuria

13 February 2025 - Fabhalta is the first oral monotherapy for previously treated and treatment naïve adults with paroxysmal nocturnal haemoglobinuria. ...

Read more →

Health Canada approves Merck's Keytruda (pembrolizumab) for the treatment of adult patients with resectable Stage II, IIIA, or IIIB (T3-4N2) non-small cell lung carcinoma (NSCLC) in combination with platinum-containing chemotherapy as neo-adjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery

11 February 2025 - Approval is based on the Phase 3 KEYNOTE-671 trial. ...

Read more →

Medexus and Ontario's Provincial Health Services successfully complete agreements for public reimbursement of Trecondyv (treosulfan for injection) in Ontario, Canada

4 February 2025 - Medexus recently completed listing agreements with Ontario's Ministry of Health (Ontario Public Drug Programs) and Ontario ...

Read more →

Refined interpretation of the Mutual Recognition Agreement between Canada and Switzerland

31 January 2025 - Swissmedic and Health Canada agreed to expand their approach regarding the implementation of the current mutual ...

Read more →

Drugs for rare diseases – Ontario agreement

24 January 2025 - Today, the Governments of Canada and the province of Ontario signed the National Strategy for Drugs ...

Read more →

Albertan with rare blood cancer calls on Health Canada to approve life-saving drug

20 January 2025 - An Alberta woman living with a rare form of blood cancer is calling on Health Canada ...

Read more →

Takeda's Fruzaqla (fruquintinib) receives Health Canada market authorisation for metastatic colorectal cancer

20 January 2025 - Positive reimbursement recommendations by Canada's Drug Agency and Institut National d'excellence en Santé et Services Sociaux. ...

Read more →

Health Canada authorises Vabysmo (faricimab injection) pre-filled syringe for three leading causes of vision loss

20 January 2025 - Vabysmo pre-filled syringe is the first and only syringe pre-filled with a Health-Canada approved bispecific antibody to ...

Read more →

Long wait for cancer drug approvals causing 'great anguish' among patients, doctors

18 January 2025 - Potentially life-saving treatments delayed by bureaucracy, doctors say. ...

Read more →

Health Canada approves Otsuka and Lundbeck's Abilify Asimtufii (aripiprazole), the first and only, once every two months, long-acting injectable treatment for schizophrenia and for maintenance monotherapy of bipolar I disorder in adults

17 January 2025 - Otsuka Pharmaceutical Canada and Lundbeck Canada announce that Health Canada has issued a Notice of Compliance ...

Read more →

Rybrevant plus chemotherapy approved in Canada as first and only targeted treatment to reduce risk of disease progression or death by more than half in second-line EGFR mutated advanced lung cancer

16 January 2025 - Phase 3 MARIPOSA-2 study showed Rybrevant in combination with carboplatin and pemetrexed significantly improved progression-free survival compared ...

Read more →

CAR T cell therapy Breyanzi (lisocabtagene maraleucel) approved for second-line relapsed or refractory diffuse large B-cell lymphoma

13 January 2024 - In the pivotal Phase 3 TRANSFORM trial, Breyanzi demonstrated a significant improvement in event-free survival over ...

Read more →

International collaboration provides new guidance on the use of surrogate endpoints in cost effectiveness analysis

9 January 2025 - Recommendations will help organisations that appraise new drugs establish whether their use will result in longer-term ...

Read more →

Astellas receives Health Canada approval for Vyloy (zolbetuximab) in combination with chemotherapy for advanced gastric and gastro-oesophageal junction cancer

9 January 2024 - Canada's Drug Agency recently issued draft recommendation to reimburse Vyloy with conditions. ...

Read more →